Document is current
Any future updates will be listed below
-
Authors
Aliyev, Elbay
Avvaru, Akshay
De Coster, Wouter
Arner, Garrison M.
Nyaga, Denis M.
Gibson, Sophia B.
Weisburd, Ben
Gu, Bida
Gonzaga-Jauregui, Claudia
,
Gustafson, Jonas A.
Goffena, Joy
Clarke, Wayne E.
Eichler, Evan E.
Nelson, Theodore M.
Snead, Anthony A.
Peng, Xinxia
Ayllon, Marcelo
Damaraju, Nikhita
Zalusky, Miranda PG
Hoekzema, Kendra
Twesigomwe, David
Yang, Lei
Richmond, Phillip A.
Olson, Nathan D.
Guarracino, Andrea
Li, Qiuhui
Miller, Angela L.
Anderson, Zachary B.
Storz, Sophie HR
Basile, Anna O.
Corvelo, André
Reeves, Catherine E.
Helland, Adrienne
Musunuri, Rajeeva Lochan
Revsine, Mahler
Patterson, Karynne E.
Paschal, Cate R.
Zakarian, Christina
Goodwin, Sara
Jensen, Tanner D.
Robb, Esther
McCombie, W. Richard
Sedlazeck, Fritz J.
Zook, Justin M.
Montgomery, Stephen B.
Garrison, Erik
Kolmogorov, Mikhail
Schatz, Michael C.
McLaughlin, Richard N. Jr
Zody, Michael C.
Loose, Matthew
Jain, Miten
Patro, Rob
Jacques, Caitlin N.
Chaisson, Mark J. P.
Miller, Danny E.
Ostrowski, Elizabeth
Dashnow, Harriet
-
Funding
Funding for this research was provided by:
Flanders Fund for Scientific Research (12ASR24N)
National Human Genome Research Institute (R25HG012994)
National Human Genome Research Institute (4R00HG012796-03)
National Institute of Dental and Craniofacial Research (DP5OD033357)
National Health and Medical Research Council (GNT2026126)
- License Information
-
More Information
Article History
Received: 28 February 2026
Accepted: 15 July 2026
First Online: 4 August 2026
Declarations
Ethics approval and consent to participate: Not applicable.
Consent for publication: Not applicable.
Competing interests: DEM is on scientific advisory boards at Basis Genetics and Inso Biosciences, is engaged in research agreements with Oxford Nanopore Technologies (ONT), PacBio, and Illumina, and has received research and travel support from ONT, PacBio, and Illumina. DEM receives research funding from BioMarin for serving as the site PI on a clinical trial. DEM holds stock options in MyOme, Basis Genetics, and Inso Biosciences, and is a consultant for MyOme. The remaining authors declare no competing interests.
